News & Events
Wednesday November 14, 2018
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo -Results were consistent across both pivotal Phase 3 studies (ELARIS UF-1 and ELARIS UF-2) - FDA New Drug Application submission anticipated in mid-2019 NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials (ELARIS UF-1 (M12-815) and ELARIS UF-2 (M12...
Wednesday November 07, 2018
Live Audio Webcast will be on November 14, 2018 SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2018 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on Wednesday, Nov. 14, 2018, in London. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximate...
Monday November 05, 2018
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx Expanded Clinical Development Pipeline - Phase I Studies Initiated with a Novel VMAT2 Inhibitor and a First-in-Class CNS Compound SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2018, and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs. "We remain committed to delivering hope for patients with serious unmet medical needs as evidenced by the growing adoption of INGREZZA and the recent commerci...
Tuesday October 23, 2018
Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress
New Data Also Examine the Impact of Uncontrollable Movements as Reported by Patients, Caregivers and Healthcare Providers from RE-KINECT, the Largest Real-World Screening Study of Patients with Possible Tardive Dyskinesia SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new data analyses on the long-term effects of INGREZZA® (valbenazine) capsules in adults with tardive dyskinesia (TD) and from RE-KINECT, the largest real-world screening study of patients with possible TD. INGREZZA is the first U.S. Food and Drug Administration (FDA) approved treatment for adults with TD, a movement disorder that is characterized by uncon...
Monday October 15, 2018
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Monday, November 5 SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9176 (US) or 785-424-1667 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investor...
Wednesday November 14, 2018